[Ala1,3,11,15]-Endothelin-1 (trifluoroacetate salt)
(Synonyms: 4-Ala-ET-1,Ala1,3,11,15-ET-1) 目录号 : GC91858[Ala1,3,11,15]-Endothelin-1 is an endothelin receptor type B (ETB) agonist and linear synthetic peptide derivative of endothelin-1 in which all four cysteine residues have been substituted with alanine.
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
[Ala1,3,11,15]-Endothelin-1 is an endothelin receptor type B (ETB) agonist and linear synthetic peptide derivative of endothelin-1 in which all four cysteine residues have been substituted with alanine.[1] It selectively binds to ETB over ETA receptors (IC50s = 0.33 and 570 nM, respectively, for the porcine receptors). [Ala1,3,11,15]-Endothelin-1 (10 and 100 nM) increases wound closure percentage in a scratch assay using human umbilical vein endothelial cells (HUVECs).[2] It increases body temperature in conscious rabbits when administered at doses of 0.15 or 0.3 nmol/kg.[3] [Ala1,3,11,15]-Endothelin-1 (20 nmol/kg, i.v.) induces bronchoconstriction and increases mean arterial blood pressure in anesthetized guinea pigs.[4] It has been used to determine the cross reactivity of monoclonal antibodies against endothelin in enzyme immunometric assays.[5]
References:
[1].Saeki, T., Ihara, M., Fukuroda, T., et al.[Ala1,3,11,15]Endothelin-1 analogs with ETB agonistic activityBiochem. Biophys. Res. Commun.179(1)286-292(1991).
[2].Wren, A.D., Hiley, C.R., and Fan, T.P.Endothelin-3 mediated proliferation in wounded human umbilical vein endothelial cellsBiochem. Biophys. Res. Commun.196(1)369-375(1993).
[3].Koshi, T., Edano, T., Arai, K., et al.Pyrogenic action of endothelin in conscious rabbitBiochem. Biophys. Res. Commun.186(3)1322-1326(2024).
[4].Noguchi, K., Noguchi, Y., Hirose, H., et al.Role of endothelin ETB receptors in bronchoconstrictor and vasoconstrictor responses in guinea-pigsEur. J. Pharmacol.233(1)47-51(1993).
[5].Pradelles, P., Grassi, J., Créminon, C., et al.Immunometric assay of low molecular weight haptens containing primary amino groupsAnal. Chem.66(1)16-22(1994).
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.4224 mL | 2.1118 mL | 4.2235 mL |
5 mM | 0.0845 mL | 0.4224 mL | 0.8447 mL |
10 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。